ART-AD Study

A new approach to dementia treatment- targeting the proteins connected to memory loss.

Overview

Patients will receive 3TC, an FDA-approved drug commonly prescribed for HIV and Hepatitis B.
Research shows that 3TC slows the disease mechanisms present in the early phases of Alzheimer’s disease.
Over the course of this trial, we will measure the success of the drug in preventing further neurodegeneration.

Eligibility

Qualifications to participate include, but are not limited to:

• Adults ages 50-80 years
• Clinical diagnosis of early Alzheimer’s disease
• Have a reliable informant or caregiver

If participants are taking Alzheimer’s medications, they must be on a stable dose for at least 8 weeks before first screening visit.

Non-eligibility

Disqualifications to participate include, but are not limited to:

• • Patients taking memantine medication

Process

Treatment will include 8 study visits over 6-7 months.
The 6-7 months will include 30 days of pre-treatment, a 24-week treatment period and a follow up visit one month following treatment.

Pre-treatment visits include:

• • • Comprehensive neuropsychological exams
    • Tablet-based neuropsychological exams
    • Lumbar puncture to collect cerebrospinal fluid
    • Blood draw

During treatment, visits include:

• • • Review of medication
    • Physical examinations
    • Brief cognitive screenings
    • Blood draw

The post-treatment visit one month after the final dose of medication includes a:

• • Comprehensive neuropsychological exam
  • Lumbar puncture to collect cerebrospinal fluid
  • Blood draw
  • Disenrollment

Meet Your Clinical Research Team

Bess Frost, PhD

Sarah C. Hopp, PhD

Nicolas Musi, MD

A. Campbell Sullivan, PSYD, ABPP-CN